Historical record - last NADAC effective date: 7/16/2015
Product Information
NEUPOGEN 300 MCG/0.5 ML SYR is a brand product labeled by Amgen Inc., priced at $632.3279 per ML under NDC 55513092410. Its NADAC has been published 137 times since Nov 28, 2013.
Strength
300 ug/.5mL
Manufacturer
Amgen Inc.NDC
55513092410
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
INTRAVENOUS; SUBCUTANEOUS
Effective Date
7/16/2015
Active Ingredients
FILGRASTIMApproval Type
Biologic (BLA)
FDA Application
BLA103353On Market Since
10/2/2000
Pharmacological Classes
Price Statistics
The NADAC for NEUPOGEN 300 MCG/0.5 ML SYR has been published 137 times since Nov 28, 2013, and over the history we have for it it has risen 4.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $632.3279 per ML |
|---|---|
| All-time high | $632.3279 (Jul 13, 2016) |
| All-time low | $604.7416 (Nov 28, 2013) |
| Median price | $622.9708 |
| Average price | $619.6024 |
| Largest weekly change | +2.0% (Jan 28, 2015) |
| Weeks tracked | 137 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+4.6%
Last surveyed Jul 13, 2016 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 52% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Amgen Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Filgrastim market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Leukocyte Growth Factor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NEUPOGEN 300 MCG/0.5 ML SYR?
The current National Average Drug Acquisition Cost (NADAC) for NEUPOGEN 300 MCG/0.5 ML SYR, manufactured by Amgen Inc., is $632.3279 per ML (NDC 55513092410), effective Jul 13, 2016.
How has the price of NEUPOGEN 300 MCG/0.5 ML SYR changed over time?
Over the history we have for it, the NADAC for NEUPOGEN 300 MCG/0.5 ML SYR has risen 4.6%. It has been tracked across 137 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for NEUPOGEN 300 MCG/0.5 ML SYR?
Since Nov 28, 2013, the NADAC for NEUPOGEN 300 MCG/0.5 ML SYR has ranged from a low of $604.7416 (Nov 28, 2013) to a high of $632.3279 (Jul 13, 2016), with a median of $622.9708 per ML.
Are there cheaper alternatives to NEUPOGEN 300 MCG/0.5 ML SYR?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, NEUPOGEN 300 MCG/ML VIAL, is $304.0908 per ML — about 52% below NEUPOGEN 300 MCG/0.5 ML SYR.
Who manufactures NEUPOGEN 300 MCG/0.5 ML SYR?
NEUPOGEN 300 MCG/0.5 ML SYR (NDC 55513092410) is labeled by Amgen Inc., and CMS classifies it as a brand product.